



October 18, 2021

Company name: SanBio Co., Ltd.
Representative: Keita Mori, Representative Director
and President
(TSE Mothers Code: 4592)
Contact: Yoshihiro Kakutani, Corporate Officer
of Management Administration
(TEL. +81-3-6264-3481)

Notice on Appointment of New Corporate Officer

SanBio Company Limited (hereafter, “the Company”) hereby announces the appointment of a new corporate officer, effective November 1, 2021, as outlined below and in the attached document.

1. New corporate officer (effective November 1, 2021)

Name	Position and roles
Naoki Tsukahara	Corporate Officer Business Head (Japan/Asia)

2. Career summary of Naoki Tsukahara, new Corporate Officer and Business Head (Japan/Asia)

Name	Career summary	
Naoki Tsukahara	April 1994	Joined Nissan Motor Co., Ltd.
	July 2003	Joined Eli Lilly Japan K.K.
	January 2012	Appointed General Manager of Musculoskeletal Business Unit, Forteo Brand Team, Eli Lilly Japan
	April 2014	Appointed General Manager of Fluoxetine Brand Team, Marketing Division, Eli Lilly Japan
	December 2014	Joined Bristol-Myers Squibb K.K. Appointed Senior Director of Immunology Franchise, Bristol-Myers Squibb
	October 2017	Appointed Asia Strategy Lead (Executive Director), Worldwide Commercial Oncology Strategy, Bristol-Myers Squibb (NJ, USA)
	April 2018	Appointed Worldwide Commercial Lead (Executive Director), Hematology, Bristol-Myers Squibb (NJ, USA)
	April 2019	Joined Abbott Japan LLC Appointed Head of Commercial Excellence Headquarters, Abbot Japan
	November 2021	Slated to join the Company



Naoki Tsukahara to Join SanBio as Corporate Officer and Business Head (Japan/Asia)

Tokyo, Japan, Mountain View, Calif., and Singapore – October 18, 2021 - The SanBio Group (SanBio Co., Ltd. and subsidiaries SanBio, Inc. and SanBio Asia Pte. Ltd.) (TSE:4592), hereby announces that Mr. Naoki Tsukahara will join the Group as a new corporate officer and business head of Japan and Asia operations of SanBio Co., Ltd. (hereafter, “the Company”) on November 1, 2021.

During his time at Eli Lilly Japan and Bristol-Myers Squibb, Mr. Tsukahara brought multiple products in a range of therapeutic areas from osteoporosis and rheumatoid arthritis to blood cancer not only to the Japanese market but also to overseas markets, and led business revitalization initiatives to success. At Abott Japan, as the Head of Commercial Excellence Headquarters, he spearheaded the moves to expand Abott’s salesforce and customer marketing and distribution strategies. In addition to growing sales of key products, he promoted business development aimed at future growth and succeeded in reforming various in-house organizations and systems for product commercialization.

The SanBio Group is aiming to obtain marketing approval for its regenerative medicine SB623 as a regenerative medicinal product. Mr. Tsukahara will be in charge of making preparations for the launch of SB623 as a treatment for chronic effects arising from traumatic brain injury in Japan ahead of the rest of the world, and establishing a sales infrastructure after the launch. He will also oversee overall operations for expanding the Group’s business in other parts of Asia.

Mr. Tsukahara commented as follows on joining the Company.

I’m excited to take part in SanBio’s efforts to develop and expand markets for SB623—the first regenerative medicine product for central nervous system disorders in the world—in Japan and other parts of Asia under the Company’s vision of becoming a global leader in regenerative medicine. With a mission of delivering SB623 to patients suffering from chronic motor deficit resulting from traumatic brain injury as soon as possible upon approval, I will utilize my business experience in the pharmaceuticals and medical devices industry to the fullest to develop and cultivate markets for SB623.

Keita Mori, CEO of the Company commented as below.

We are pleased to welcome on board Mr. Tsukahara who has many years of experience and a track record in launching pharmaceutical products in Japan and overseas. Under the leadership of Mr. Tsukahara, we at SanBio will put our efforts together into reinforcing our marketing infrastructure with the aim of providing SB623 to patients in need as soon as possible.

About SanBio Group (SanBio Co., Ltd., SanBio, Inc., and SanBio Asia Pte. Ltd.)

SanBio Group is engaged in the regenerative cell medicine business, spanning research, development, manufacture, and sales of regenerative cell medicines. The Company's propriety regenerative medicine SB623 is currently being investigated for the treatment of several conditions including chronic neurological motor deficit resulting from traumatic brain injury and stroke. The Company is headquartered in Tokyo with offices in Mountain View, California and Singapore. For more information, please visit us at <https://sanbio.com/en/>.

For more information, contact:

SanBio Co., Ltd.

Management Administration

info@sanbio.jp